- Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Bendamustine Hydrochloride
Sponsors: Teva Pharmaceutical Industries; Cephalon
Not yet recruiting - verified May 2012 - Condition: Drug Abuse
Intervention: Drug: 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)
Sponsors: Teva Pharmaceutical Industries; Cephalon
Completed - verified May 2012 - Condition: Extensive-stage Small Cell Lung Cancer
Interventions: Drug: Obatoclax Mesylate, Carboplatine and Etoposide; Drug: Carboplatin and Etoposide
Sponsors: Teva Pharmaceutical Industries; Cephalon
Not yet recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Intervention:
Sponsors: Teva Pharma; Teva Pharma
Recruiting - verified May 2012 - Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Matching Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Condition: Menopause
Intervention: Drug: Armodafinil
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Cephalon
Recruiting - verified October 2011 - Conditions: Lung Cancer; Cancer of Lung; Pulmonary Cancer; Pulmonary Neoplasms; Carcinoma, Small Cell
Intervention: Drug: Arsenic Trioxide
Sponsors: Emory University; Emory University; Cephalon
Recruiting - verified May 2012 - Conditions: Solid Tumour; Adenocarcinoma of the Colon; Adenocarcinoma of the Pancreas
Intervention: Drug: CEP-37250/KHK2804
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Cephalon
Recruiting - verified February 2012 - Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
Interventions: Drug: Carboplatin; Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
Sponsors: German Breast Group; German Breast Group; Cephalon; Roche Pharma AG; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Cancer Pain
Intervention: Drug: Effentora®
Sponsors: Cephalon; Cephalon
Recruiting - verified February 2012 - Condition: Malignant Glioma
Interventions: Drug: Nuvigil®; Drug: Placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Cephalon
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Arsenic trioxide
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH); Cephalon
Recruiting - verified March 2012 - Condition: Epilepsy
Intervention: Drug: Anti-epileptic drug (AED)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel; Drug: Trastuzumab, Docetaxel, Bevacizumab; Drug: Trastuzumab+Docetaxel+NPLD; Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Hoffmann-La Roche; Cephalon
Recruiting - verified April 2012
 |
Cephalon - Database of Clinical Trials by Pharmaceutical Companies |
